Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03155620
Title	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	sarcoma non-Hodgkin lymphoma lymphoma medulloblastoma hepatoblastoma rhabdomyosarcoma neuroectodermal tumor Advanced Solid Tumor lymphatic system cancer Ewing sarcoma childhood ependymoma central nervous system cancer neuroblastoma childhood osteosarcoma
Therapies	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib
Age Groups:	adult \| child
Covered Countries	USA \| CAN \| AUS